February 17, 2005 Stocks suffered a late slide on Thursday, taking them from levels that were only slightly negative at mid-day down to a larger loss at the close. The Centient Biotech 200 lost almost 42 points to 3322.24, a 1.24% drop. Despite the decline in the indexes, individual companies had good news to present to investors. For example, Dendreon reported good survival numbers for its prostate cancer vaccine, Sepracor is being talked about as a takeover candidate, Tysabri from Elan and Biogen Idec showed results in two-year tests that were just as good as the one-year trials, and Cell Therapeutics said it would speed up release of the Phase III data on its targeted reformulation of paclitaxel. We give more detail...
